Which has stronger earnings and valuation, BTMD or LFMD?

biote has higher earnings, but lower revenue than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $183.53M 0.23 $27.05M $0.11 10.45 LifeMD $194.05M 0.65 $14.35M -$0.05 N/A

Is BTMD or LFMD more profitable?

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets biote 3.19% -22.33% 12.10% LifeMD 0.10% -168.23% -31.27%

Does the media prefer BTMD or LFMD?

In the previous week, biote and biote both had 3 articles in the media. LifeMD's average media sentiment score of 0.67 beat biote's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BTMD or JYNT?

biote currently has a consensus price target of $2.50, suggesting a potential upside of 117.39%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, BTMD or JYNT?

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $183.53M 0.23 $27.05M $0.11 10.45 Joint $54.90M 1.81 $2.91M $0.27 26.07

Is BTMD or JYNT more profitable?

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets biote 3.19% -22.33% 12.10% Joint 6.49% 12.02% 3.47%

Does the media refer more to BTMD or JYNT?

In the previous week, biote and biote both had 3 articles in the media. biote's average media sentiment score of 0.00 equaled Joint'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PRPO or BTMD?

biote has a consensus target price of $2.50, indicating a potential upside of 117.39%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings & valuation, PRPO or BTMD?

biote has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 1.72 -$360K -$0.64 N/A biote $183.53M 0.23 $27.05M $0.11 10.45

Is PRPO or BTMD more profitable?

biote has a net margin of 3.19% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% biote 3.19% -22.33% 12.10%

Does the media refer more to PRPO or BTMD?

In the previous week, biote had 1 more articles in the media than Precipio. MarketBeat recorded 3 mentions for biote and 2 mentions for Precipio. Precipio's average media sentiment score of 0.85 beat biote's score of 0.00 indicating that Precipio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PIII or BTMD more profitable?

biote has a net margin of 3.19% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% biote 3.19% -22.33% 12.10%

Does the media prefer PIII or BTMD?

In the previous week, P3 Health Partners and P3 Health Partners both had 3 articles in the media. P3 Health Partners' average media sentiment score of 0.00 equaled biote'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

biote (BTMD) Competitors

$1.15 -0.02 (-1.71%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.87%)

As of 10/9/2026 07:30 PM Eastern

Compare

BTMD vs. LFMD, JYNT, PARK, PRPO, and PIII

Should you buy biote stock or one of its competitors? biote's main competitors and comparable companies include LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), Precipio (PRPO), and P3 Health Partners (PIII). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does biote compare to LifeMD?

biote (NASDAQ:BTMD) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

biote has a net margin of 3.19% compared to LifeMD's net margin of 0.10%. biote's return on equity of -22.33% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
LifeMD	0.10%	-168.23%	-31.27%

biote has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

In the previous week, biote and biote both had 3 articles in the media. LifeMD's average media sentiment score of 0.67 beat biote's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

biote presently has a consensus price target of $2.50, suggesting a potential upside of 117.39%. LifeMD has a consensus price target of $7.57, suggesting a potential upside of 187.89%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

biote has higher earnings, but lower revenue than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$183.53M	0.23	$27.05M	$0.11	10.45
LifeMD	$194.05M	0.65	$14.35M	-$0.05	N/A

21.7% of biote shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

biote and LifeMD tied by winning 8 of the 16 factors compared between the two stocks.

How does biote compare to Joint?

biote (NASDAQ:BTMD) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

biote has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Joint has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

biote has higher revenue and earnings than Joint. biote is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$183.53M	0.23	$27.05M	$0.11	10.45
Joint	$54.90M	1.81	$2.91M	$0.27	26.07

biote currently has a consensus price target of $2.50, suggesting a potential upside of 117.39%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Joint has a net margin of 6.49% compared to biote's net margin of 3.19%. Joint's return on equity of 12.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Joint	6.49%	12.02%	3.47%

In the previous week, biote and biote both had 3 articles in the media. biote's average media sentiment score of 0.00 equaled Joint'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of biote shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 30.2% of Joint shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

biote beats Joint on 9 of the 15 factors compared between the two stocks.

How does biote compare to Park Dental Partners?

biote (NASDAQ:BTMD) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

In the previous week, biote had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 3 mentions for biote and 2 mentions for Park Dental Partners. biote's average media sentiment score of 0.00 equaled Park Dental Partners'average media sentiment score.

Company	Overall Sentiment
biote	Neutral
Park Dental Partners	Neutral

biote has higher earnings, but lower revenue than Park Dental Partners. biote is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$183.53M	0.23	$27.05M	$0.11	10.45
Park Dental Partners	$244.49M	0.39	-$360K	$1.05	19.29

biote currently has a consensus target price of $2.50, suggesting a potential upside of 117.39%. Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 40.74%. Given biote's higher probable upside, research analysts plainly believe biote is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 3.19% compared to Park Dental Partners' net margin of 0.00%. Park Dental Partners' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Park Dental Partners	N/A	N/A	N/A

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 10.6% of Park Dental Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

biote beats Park Dental Partners on 7 of the 12 factors compared between the two stocks.

How does biote compare to Precipio?

Precipio (NASDAQ:PRPO) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

biote has a consensus target price of $2.50, indicating a potential upside of 117.39%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Precipio has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, biote has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

biote has a net margin of 3.19% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
biote	3.19%	-22.33%	12.10%

In the previous week, biote had 1 more articles in the media than Precipio. MarketBeat recorded 3 mentions for biote and 2 mentions for Precipio. Precipio's average media sentiment score of 0.85 beat biote's score of 0.00 indicating that Precipio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.5% of Precipio shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 16.6% of Precipio shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

biote has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	1.72	-$360K	-$0.64	N/A
biote	$183.53M	0.23	$27.05M	$0.11	10.45

Summary

biote beats Precipio on 14 of the 17 factors compared between the two stocks.

How does biote compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

biote has a net margin of 3.19% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
biote	3.19%	-22.33%	12.10%

In the previous week, P3 Health Partners and P3 Health Partners both had 3 articles in the media. P3 Health Partners' average media sentiment score of 0.00 equaled biote'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

biote has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.50B	0.02	-$147.95M	-$33.00	N/A
biote	$183.53M	0.23	$27.05M	$0.11	10.45

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

P3 Health Partners has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, biote has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

P3 Health Partners presently has a consensus price target of $17.00, suggesting a potential upside of 243.43%. biote has a consensus price target of $2.50, suggesting a potential upside of 117.39%. Given P3 Health Partners' higher probable upside, equities analysts plainly believe P3 Health Partners is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

biote beats P3 Health Partners on 10 of the 14 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.04M	$9.80B	$7.16B	$13.21B
Dividend Yield	N/A	2.61%	2.53%	16.36%
P/E Ratio	10.46	33.98	274.13	26.16
Price / Sales	0.23	4.87	590.44	94.78
Price / Cash	2.02	115.75	76.38	53.09
Price / Book	-0.82	5.11	11.21	6.34
Net Income	$27.05M	$315.68M	$3.50B	$381.90M
7 Day Performance	N/A	-0.40%	-0.92%	-1.41%
1 Month Performance	-12.21%	-1.99%	-4.46%	-3.48%
1 Year Performance	-58.48%	12.74%	6.94%	1.16%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.309 of 5 stars	$1.15 -1.7%	$2.50 +117.4%	-59.8%	$42.04M	$183.53M	10.46	223
LFMD LifeMD	2.8497 of 5 stars	$2.73 +0.4%	$7.57 +177.3%	-59.7%	$131.59M	$191.59M	N/A	384
JYNT Joint	1.766 of 5 stars	$7.11 -1.0%	N/A	-17.0%	$100.54M	$54.90M	26.33	330
PARK Park Dental Partners	3.3403 of 5 stars	$20.53 -2.7%	$28.50 +38.8%	N/A	$97.72M	$244.49M	19.55	1,212	Positive News Short Interest Increase
PRPO Precipio	1.049 of 5 stars	$23.45 -2.3%	N/A	+17.6%	$41.98M	$24.05M	N/A	71

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors